See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

The World's First Diabetes Emergency Kit

Gillian Miller - Diabetes and More

The World's First Diabetes Emergency Kit

Diabetes and Byetta

Page 2
Sanofi Says Late-Stage Trial of Type 2 Drug a Success
May 23, 2011 | 
French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.
Study Says Byetta and Januvia Do Not Pose Extra Risk for Pancreatitis
Jul 8, 2010 | 
A study released in late June has brought some welcome news to the makers of Byetta and Januvia: Users of the two diabetes drugs run no greater risk of developing pancreatitis than people with diabetes who take other drugs. In fact, both drugs seem to put users at slightly less risk for the condition.
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

World Diabetes Day 2009

DHTV Covers World Diabetes Day in Sacramento, California

World Diabetes Day 2009

The World's First Diabetes Emergency Kit

Gillian Miller - Diabetes and More

The World's First Diabetes Emergency Kit

Amylin Hopes to Begin U.S. Sales of Long-Acting Byetta Early This Year
Mar 4, 2010 | 
Amylin Pharmaceuticals has announced that it expects to begin selling a once-weekly version of its diabetes drug, Byetta, by the end of the year. The company reports that the FDA is nearing final inspections of its manufacturing plant and could give the go-ahead for U.S. sales in early March.
Liraglutide Tested on African Americans with Type 2 Diabetes
Aug 6, 2009 | 
Most clinical studies of new drugs are conducted primarily on white men, whether or not they are most affected by the disease the drug is intended to treat.  African Americans, for example, are 1.6 times more likely to have diabetes than non-Hispanic whites.  Why should we assume that what works for white males will also be effective for African Americans, Hispanics, Asians, or, for that matter, women?
Survey Says Most Endocrinologists and Physicians See a Need for More Byetta and Januvia-Type Drugs
Jul 25, 2009 | 
High percentages of endocrinologists, primary care physicians, and managed care organizations surveyed by a research firm say they would like to see additional GLP-1 analogues like Amylin/Eli Lilly's Byetta® and DPP-IV inhibitors like Merck's Januvia® available to treat type 2 diabetes.
Amylin Cuts Workforce, Asks FDA to Approve Once-Weekly Byetta
May 11, 2009 | 
It has been an interesting month for San Diego-based Amylin Pharmaceuticals Inc., the co-manufacturer of Byetta (exenatide) with Eli Lilly & Co., and Alkermes Inc. First, the company announced that it will reduce its sales force by 35 percent-200 employees-in hope of saving $20 million this year and $45 million annually starting in 2010. The company plans to retain 325 representatives to sell its diabetes products to doctors and endocrinologists. At the same time, Amylin has petitioned the FDA to approve the marketing of Byetta LAR, a form of the type 2 drug that requires injection only once a week.
Type 2 Drugs: EU Approves “Victoza,” FDA Extends Review of “Onglyza”
May 6, 2009 | 
The European Union's drug regulation agency has recommended that the EU approve the marketing of "Victoza" (liraglutide), a type 2 drug developed by Novo Nordisk.
Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.